World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Zymo Research and STORI Advance Early Pregnancy Detection with Cell-Free DNA Technology

Cision PR Newswire by Cision PR Newswire
April 7, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

IRVINE, Calif., April 7, 2026 /PRNewswire/ — Zymo Research, a global leader in life science technologies, and STORI, a new women’s health company, today announced a collaboration to bring a novel early pregnancy assay to market, enabling detection of placental-derived DNA in maternal blood as early as five weeks of gestation.


Zymo Research and STORI's collaboration brings a novel early pregnancy assay to market, enabling detection of placental-derived DNA in maternal blood as early as five weeks of gestation.

The assay was developed using molecular biology technologies and workflow infrastructure developed by Zymo Research, integrating optimized sample preservation, cell-free DNA extraction chemistry, assay design, and computational analysis. Each stage of the workflow was engineered to enable reliable recovery and detection of low-abundance circulating DNA fragments during early gestation.

“Detecting fetal DNA at such early stages of pregnancy, when the embryo is approximately the size of a poppy seed, required rethinking nearly every step of the workflow,” said Paolo Piatti, PhD, Director of Applied Epigenetics at Zymo Research. “The ability to reliably recover and capture these extremely low-abundance signals opens new possibilities for highly sensitive circulating DNA analysis.”

“Early pregnancy is a period where biological signals are already present, but difficult to measure,” said Sabina Melarti, CEO at STORI. “The value of early insight lies not just in getting an answer sooner, but, more importantly, in receiving that answer with the highest possible degree of accuracy and responsibility. Working with Zymo allows fetal cell-free DNA to be measured with the sensitivity and care required to make that possible.”

Under the agreement, STORI will serve as the exclusive commercialization partner, bringing to market an assay powered by Zymo Research’s technology through its reproductive health platform. The offering will support at-home capillary blood collection to expand access to early-stage testing, with initial applications such as prenatal biological sex determination. 

Preliminary analytical validation has been completed, and additional IRB-approved clinical studies are underway to further characterize assay performance and gestational sensitivity.

This collaboration highlights how Zymo Research empower partners and innovators with the molecular technologies and workflow foundations that unlock advantages in diagnostics and drive innovation across the broader health and life sciences landscape.

About Zymo Research Corp.

Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle “The Beauty of Science is to Make Things Simple,” Zymo Research is dedicated to developing innovative solutions that address complex scientific challenges.

Known also as The Epigenetics Company, Zymo Research offers a comprehensive range of technologies, including solutions for sample collection, DNA/RNA purification, library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services.

In addition to its cutting-edge technologies, Zymo Research is committed to sustainability. By engineering environmentally friendly solutions, the company strives to reduce waste and contribute to a more sustainable future through scientific innovation.

For more information, please visit www.zymoresearch.com

About STORI

STORI is a women’s health company focused on early human developmental biology. The company translates molecular signals into accessible biological insight, pairing scientific rigor with responsible, human-centered interpretation and application.

Its work spans early biological systems across the perinatal arc, from fertility through pregnancy and early life.

For more information, please visit www.ourstori.com


Zymo Research Corp. Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zymo-research-and-stori-advance-early-pregnancy-detection-with-cell-free-dna-technology-302735045.html

SOURCE Zymo Research Corp.

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • How to Go 2x Long Anthropic (ANT): Leverage Shares by Themes Explains ANUU, the 2x Leveraged Anthropic ETF Launching Monday

    0 shares
    Share 0 Tweet 0
  • Mendez & Sanchez Finds Three Counties Accounted for Nearly Two-Thirds of California Rideshare Trips

    0 shares
    Share 0 Tweet 0
  • Highmark Health Reports Revenue of $26.5 billion, $741 million in Operating Income, for Nine Months ended Sept. 30, 2026

    0 shares
    Share 0 Tweet 0
  • AZ Blue Health Choice Expands Access to Resources for Page Families

    0 shares
    Share 0 Tweet 0
  • Payoneer Receives OCC Conditional Approval to Form Stablecoin National Trust Bank

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler